Am J Transplant, Volume 18, Suppl 3 Archives - Page 10 of 211 - ATC Abstracts

2018 American Transplant Congress
Upper Limb and Craniofacial VCA Donors in the US
J. Wainright, C. Wholley, W. Cherikh, J. Rosendale, D. Klassen.
UNOS, Richmond.
Life changing VCA transplants are made possible by deceased VCA donors. This study provides the first description of all known upper limb and craniofacial donors…
2018 American Transplant Congress
Rhesus Monkey Have natural Antibody toward Swine That is Not Influenced by Allosensitization nor by Carfilzomib/tocilizumab
J. Yoon, B. Ezekian, M. Manook, J. Kwun, S. Knechtle.
Surgery, Duke University, Durham, NC.
[Background] Pre-formed antibody is a substantial immunological barrier in organ transplantion. Antibodies to xenoantigens can lead to rapid antibody-mediated rejection (AMR) in xenotransplantation. We previously…
2018 American Transplant Congress
DSA Plus TCMR Leads to Poor Outcomes in Renal Allograft Recipients and This is Markedly Exacerbated by Non-Adherence
D. Chittka, A. Cherukuri, A. Sharma, R. Mehta, S. Hariharan, D. Rothstein.
Starzl Transplant Institute, University of Pittsburgh, Pittsburgh.
Post-transplant DSA is strongly associated with poor renal allograft outcomes but has limited predictive value. In this prospective study we aimed to risk-stratify patients with…
2018 American Transplant Congress
De Novo Donor Specific Antibodies in Pediatric Kidney Transplant Recipients Are Highly Responsive to Therapy
V. Sigurjonsdottir, P. Grimm.
Pediatric Nephrology, Lucile Packard Children´s Hospital, Palo Alto, CA.
Background: Pediatric Kidney transplant recipients who develop dnDSAs are at increased risk of allograft loss and rapid decline in GFR. C1q+ DSA, in particular, is…
2018 American Transplant Congress
Patients Prioritize Waitlist Factors over Outcomes When Evaluating Kidney Transplant Centers
A. Michelson, C. Brennan, A. Mattoo, B. Kil, D. Tsapepas, S. Husain, S. Mohan.
Nephrology, Columbia University Medical Center, New York, NY.
The factors that influence transplant candidates' selection of a transplant center for waitlisting are not well understood. Further, the relative weightage of these factors has…
2018 American Transplant Congress
Early Conversion to a CNI-Free Immunosuppression with SRL after Renal Tx – 10 yr Follow-Up Analysis of a Prospective Multicenter Trial
J. Andrassy,¹ M. Guba,¹ A. Habicht,² M. Fischereder,³ A. Pascher,⁴ K. Heller,⁵ B. Banas,⁶ O. Hakenberg,⁷ T. Vogel,⁸ T. Kauke.¹
¹Surgery, Ludwig-Maximilans-University, Munich, Germany; ²Transplant, Ludwig-Maximilans-University, Munich, Germany; ³Nephrology, MED IV, Ludwig-Maximilans-University, Munich, Germany; ⁴Surgery, Charitée University, Berlin, Germany; ⁵Medicine, University of Erlangen, Erlangen, Germany; ⁶Internal Medicine II, University of Regensburg, Regensburg, Germany; ⁷Urology, University of Rostock, Rostock, Germany; ⁸Surgery, University of Munster, Munster, Germany.
Introduction: A prospective multicenter trial comparing an early conversion to a CNI-free immunosuppression with SRL, MMF and steroids with a conventional CsA treatment following renal…
2018 American Transplant Congress
The Effect of Tacrolimus Trough Level and Intrapatient Variability on the Transplant Outcomes in Kidney Transplantation
J. Lee,¹ J. Lee,¹ Y. Jung,¹ D. Kim,¹ S. Song,² J. Lee,³ J. Lee,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ B. Kim,⁴ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ³Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁴Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Tacrolimus (TAC) is the mainstay of immunosuppression for kidney transplantation (KT). Although TAC has a narrow therapeutic index, appropriate trough concentrations of TAC have…
2018 American Transplant Congress
Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant
Y. Lu,¹ J. Lyons,² S. Tischer,² K. Woodside,³ J. Park.²
¹Transplant Nephrology, University of Michigan, Ann Arbor, MI; ²Transplant Pharmacy, University of Michigan, Ann Arbor, MI; ³Transplant Surgery, University of Michigan, Ann Arbor, MI.
Background: For patients with end stage renal disease (ESRD) due to primary focal segmental glomerulosclerosis (FSGS), there is a significantly increased risk for disease recurrence…
2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
M. Benincasa,¹ V. Colomy,¹ N. Sifontis,¹ S. Rao,² K. Lau,³ S. Karhadkar,³ A. Di Carlo,³ A. Diamond.⁴
¹Pharmacy Practice, Temple School of Pharmacy, Philadelphia, PA; ²Medicine, Temple School of Medicine, Philadelphia, PA; ³Surgery, Temple School of Medicine, Philadelphia, PA; ⁴Pharmacy, Temple University Hospital, Philadelphia, PA.
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…
2018 American Transplant Congress
Evaluation of Financial Well-Being of Living Kidney Donor Candidates
S. Singh,^1,2 G. Bannerman,² A. Yantsis,² M. Liu,² F. Gumabay,² O. Famure.²
¹Division of Nephrology, Department of Medicine, University of Toronto, Toronto, ON, Canada; ²Division of Nephrology and the Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Despite the known benefits of living donor kidney transplantation, the rate of living kidney donation in Canada has not increased. Potential reasons include the lack…